MSH2 and endometrial cancer: In contrast, the cumulative risk of endometrial cancer by the age of 70 years was significantly lower for 3′ end EPCAM deletion carriers than for combined EPCAM-MSH2 deletion carriers and MSH2 mutation carriers (Table 3).